German drugmaker Stada Arzneimittel (SAZ: GR) has posted financial results for the first nine months of 2014, showing that groups sales rose 4% to 1.48 billion euros ($1.84 billion), though down 1% adjusted for currency and portfolio effects. The company’s shares dipped 1.4% to 28.12 euros by late morning trading.
Reported earnings before interest, taxes, depreciation and amortization (EMITDA) rose by 10% to 293.6 million euros, with a similar rise in net income to 99.1 million euros.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze